An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats
Tarek A Ahmed,1,2 Mohammed A Mussari,1 Seham El-Sayed Abdel-Hady,1 Khalid M El-Say1,2 1Department Of Pharmaceutics, Faculty Of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 2Department Of Pharmaceutics And Industrial Pharmacy, Faculty Of Pharmacy, Al-Azhar University, Cairo 1...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-12-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/an-optimized-surfactant-based-peg-plcl-in-situ-gel-formulation-for-enh-peer-reviewed-article-DDDT |
id |
doaj-94e4dcc84c6c4afdb239a3a4ffd805cb |
---|---|
record_format |
Article |
spelling |
doaj-94e4dcc84c6c4afdb239a3a4ffd805cb2020-11-25T00:47:15ZengDove Medical PressDrug Design, Development and Therapy1177-88812019-12-01Volume 134035405150201An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic RatsAhmed TAMussari MAAbdel-Hady SESEl-Say KMTarek A Ahmed,1,2 Mohammed A Mussari,1 Seham El-Sayed Abdel-Hady,1 Khalid M El-Say1,2 1Department Of Pharmaceutics, Faculty Of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 2Department Of Pharmaceutics And Industrial Pharmacy, Faculty Of Pharmacy, Al-Azhar University, Cairo 11651, EgyptCorrespondence: Tarek A AhmedDepartment Of Pharmaceutics, Faculty Of Pharmacy, King Abdulaziz University, PO. Box 80200, Jeddah 21589, Kingdom of Saudi ArabiaEmail tabdelnapy@kau.edu.saBackground: Injectable in situ gel (ISG) systems suffer from high initial drug release that may result in toxic effects.Objective: This work aimed to develop an injectable sustained release rosuvastatin (RSV) ISG formulation with minimum initial drug burst and improved hyperlipidemic efficacy.Methods: Six formulation factors that affect RSV release after 0.5, 2 and 24 hrs have been screened and the significant ones were optimized utilizing an experimental design tool. The optimum ISG formulation components were physicochemically characterized. Kinetic treatment, dissolution efficiency and mean dissolution time were investigated for the developed ISG formulations. Pharmacodynamic effects of the optimized ISG formulation were studied and compared to ISG formulation loaded with free RSV and to a marketed oral drug product.Results: The concentration polylactide-co-ϵ-caprolactone (25: 75), the surfactant hydrophilic lipophilic balance (HLB) and the ratio of surfactant to polyethylene glycol 400 were significantly affecting the release of RSV during the first 24 h. Physicochemical characterization demonstrated complete dispersion of RSV in the polymeric matrix with slight changes in the drug crystalline structure. The optimized formulation demonstrated acceptable syringeability, good flow rate and was able to extend the in vitro drug release for 34 days. The ISG formulations complied with Weibull model. Pharmacodynamic study revealed a sustained reduction in the lipid profile that lasted for 21 days with a marked decrease in the lipid level during the first 24 hrs from the ISG system loaded with free RSV.Conclusion: The optimized RSV ISG formulation could be considered a promising strategy due to a reduction in dosing frequency and enhancement in hypolipidemic efficacy.Keywords: hypolipidemic activity, in situ gel, initial burst, optimization, rosuvastatinhttps://www.dovepress.com/an-optimized-surfactant-based-peg-plcl-in-situ-gel-formulation-for-enh-peer-reviewed-article-DDDThypolipidemic activityin situ gelinitial burstoptimizationrosuvastatin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ahmed TA Mussari MA Abdel-Hady SES El-Say KM |
spellingShingle |
Ahmed TA Mussari MA Abdel-Hady SES El-Say KM An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats Drug Design, Development and Therapy hypolipidemic activity in situ gel initial burst optimization rosuvastatin |
author_facet |
Ahmed TA Mussari MA Abdel-Hady SES El-Say KM |
author_sort |
Ahmed TA |
title |
An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats |
title_short |
An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats |
title_full |
An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats |
title_fullStr |
An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats |
title_full_unstemmed |
An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats |
title_sort |
optimized surfactant-based peg-plcl in situ gel formulation for enhanced activity of rosuvastatin in poloxamer-induced hyperlipidemic rats |
publisher |
Dove Medical Press |
series |
Drug Design, Development and Therapy |
issn |
1177-8881 |
publishDate |
2019-12-01 |
description |
Tarek A Ahmed,1,2 Mohammed A Mussari,1 Seham El-Sayed Abdel-Hady,1 Khalid M El-Say1,2 1Department Of Pharmaceutics, Faculty Of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 2Department Of Pharmaceutics And Industrial Pharmacy, Faculty Of Pharmacy, Al-Azhar University, Cairo 11651, EgyptCorrespondence: Tarek A AhmedDepartment Of Pharmaceutics, Faculty Of Pharmacy, King Abdulaziz University, PO. Box 80200, Jeddah 21589, Kingdom of Saudi ArabiaEmail tabdelnapy@kau.edu.saBackground: Injectable in situ gel (ISG) systems suffer from high initial drug release that may result in toxic effects.Objective: This work aimed to develop an injectable sustained release rosuvastatin (RSV) ISG formulation with minimum initial drug burst and improved hyperlipidemic efficacy.Methods: Six formulation factors that affect RSV release after 0.5, 2 and 24 hrs have been screened and the significant ones were optimized utilizing an experimental design tool. The optimum ISG formulation components were physicochemically characterized. Kinetic treatment, dissolution efficiency and mean dissolution time were investigated for the developed ISG formulations. Pharmacodynamic effects of the optimized ISG formulation were studied and compared to ISG formulation loaded with free RSV and to a marketed oral drug product.Results: The concentration polylactide-co-ϵ-caprolactone (25: 75), the surfactant hydrophilic lipophilic balance (HLB) and the ratio of surfactant to polyethylene glycol 400 were significantly affecting the release of RSV during the first 24 h. Physicochemical characterization demonstrated complete dispersion of RSV in the polymeric matrix with slight changes in the drug crystalline structure. The optimized formulation demonstrated acceptable syringeability, good flow rate and was able to extend the in vitro drug release for 34 days. The ISG formulations complied with Weibull model. Pharmacodynamic study revealed a sustained reduction in the lipid profile that lasted for 21 days with a marked decrease in the lipid level during the first 24 hrs from the ISG system loaded with free RSV.Conclusion: The optimized RSV ISG formulation could be considered a promising strategy due to a reduction in dosing frequency and enhancement in hypolipidemic efficacy.Keywords: hypolipidemic activity, in situ gel, initial burst, optimization, rosuvastatin |
topic |
hypolipidemic activity in situ gel initial burst optimization rosuvastatin |
url |
https://www.dovepress.com/an-optimized-surfactant-based-peg-plcl-in-situ-gel-formulation-for-enh-peer-reviewed-article-DDDT |
work_keys_str_mv |
AT ahmedta anoptimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats AT mussarima anoptimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats AT abdelhadyses anoptimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats AT elsaykm anoptimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats AT ahmedta optimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats AT mussarima optimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats AT abdelhadyses optimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats AT elsaykm optimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats |
_version_ |
1725261006209286144 |